Details of the Drug

General Information of Drug (ID: DMPM4SK)

• Drug Name: Methamphetamine
• Synonyms: METHAMPHETAMINE; Metamfetamine; d-Deoxyephedrine; d-Desoxyephedrine; d-Methamphetamine; d-N-Methylamphetamine; Metamphetamine; L-Methamphetamine; d-Methylamphetamine; Methylamphetamine; d-Phenylisopropylmethylamine; N-Methylamphetamine; (S)-Methamphetamine; Norodin; (+)-Methylamphetamine; d-(S)-Methamphetamine; D-1-Phenyl-2-methylaminopropane; Metamfetaminum; Desyphed; (+)-N-Methylamphetamine; (S)-Methylamphetamine; (+)-(S)-Deoxyephedrine; Methyl-beta-phenylisopropylamine; 1-Phenyl-2-methylaminopropane; (S)-(+)-Deoxyephedrine; Crank; Desohyephedrine; Metamfetamina; Meth; Methamphetaminum; Speed; Stimulex; Crank [Street Name]; Crystal Meth; Crystal Meth [Street Name]; Desyphed hydrochloride; ICE [Street Name]; Metamfetamine [INN];Metamfetaminum [Latin]; Metanfetamina [Spanish]; Methamphetaminum [JP]; Speed [Street Name]; D-Deoxyephedrine; D-Desoxyephedrine; D-Methamphetamine; D-Methylamphetamine; D-Phenylisopropylmethylamine;Desoxyn (TN); Metamfetamina [INN-Spanish]; Metamfetamine (INN); Metamfetamine-m; Metamfetaminum [INN-Latin]; Metanfetamina [INN-Spanish]; Meth (Street Name); Methamphetaminum [INN-Latin]; D-N-Methylamphetamine; D-(S)-Methamphetamine; D-N,alpha-dimethylphenethylamine; Methamphetamine, its salts, isomers, and salts of its isomers; N-Methyl-beta-phenylisopropylamin; N-Methyl-beta-phenylisopropylamin [German]; N-Methyl-beta-phenylisopropylamine; D-1-Phenyl-2-methylaminopropan; D-1-Phenyl-2-methylaminopropan [German]; S-(+)-Methamphetamine; D-N,alpha-Dimethylphenethylamine; N-Methyl-1-phenyl-2-propanamine; Benzeneethanamine, N,alpha-dimethyl-, (S)-(9CI); Benzeneethanamine, N,alpha-dimethyl-, (alphaS)-(9CI); Phenethylamine, N,alpha-dimethyl-, (S)-(+)-(8CI); (+)-(S)-N-alpha-Dimethylphenethylamine; (+)-2-(N-Methylamino)-1-phenylpropane; (+)-N,alpha-Dimethyl-beta-phenylethylamine; (+)-N,alpha-Dimethylphenethylamine; (+)-methamphetamine; (2S)-N-methyl-1-phenylpropan-2-amine; (S)-(+)-Methamphetamine; (S)-(+)-N,alpha,dimethylphenethylamine; (S)-N,alpha-Dimethylbenzeneethanamine; (S)-N,alpha-Dimethylbenzeneethanoamine; (alphaS)-N,alpha-dimethylbenzeneethanamine; 1-Phenyl-2-methylamino-propan; 1-Phenyl-2-methylamino-propan [German]; 2S-(+)-Methamphetamine; Methamfetamine

Indication

Disease Entry	ICD 11	Status	REF
Attention deficit hyperactivity disorder	6A05.Z	Approved	[1], [2]
Pain	MG30-MG3Z	Approved	[3]

• Therapeutic Class: Central Nervous System Stimulants
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 149.23
  Topological Polar Surface Area (xlogp); 2.1
  Rotatable Bond Count (rotbonds); 3
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 1
• ADMET Property:
  Bioavailability: 67% of drug becomes completely available to its intended biological destination(s) [4]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 4.4 mL/min/kg [5]
  Elimination: 40% of drug is excreted from urine in the unchanged form [6]
  Half-life: The concentration or amount of drug in body reduced by one-half in 4 - 5 hours [5]
  Metabolism: The drug is metabolized via the hepatic [7]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.9228 micromolar/kg/day [8]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.85% [5]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 4.3 L/kg [5]
  Water Solubility: The ability of drug to dissolve in water is measured as 1000 mg/mL [6]
• Chemical Identifiers:
  Formula: C10H15N
  IUPAC Name: (2S)-N-methyl-1-phenylpropan-2-amine
  Canonical SMILES: C[C@@H](CC1=CC=CC=C1)NC
  InChI: InChI=1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3/t9-/m0/s1
  InChIKey: MYWUZJCMWCOHBA-VIFPVBQESA-N
• Cross-matching ID:
  PubChem CID: 10836
  ChEBI ID: CHEBI:6809
  CAS Number: 537-46-2
  DrugBank ID: DB01577
  TTD ID: D0P6UB
  VARIDT ID: DR00256
  INTEDE ID: DR1036
  ACDINA ID: D00207

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor alpha-1B (ADRA1B)	TTBRKXS	ADA1B_HUMAN	Antagonist	[9]
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Agonist	[3]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Vesicular amine transporter 2 (SLC18A2)	DTT7VPB	VMAT2_HUMAN	Substrate	[10]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[11]

Molecular Expression Atlas of This Drug

• The Studied Disease: Attention deficit hyperactivity disorder
• ICD Disease Classification: 6A05.Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49
Vesicular amine transporter 2 (SLC18A2)	DTP	VMAT2	2.69E-02	-4.44E-02	-1.12E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.30E-01	-1.91E-02	-1.41E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Methamphetamine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Tromethamine	DMOBLGK	Moderate	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Methamphetamine caused by Tromethamine mediated altered urine pH.	Acidosis [5C73]	[44]
Methylene blue	DMJAPE7	Major	Increased risk of hyperpyrexia by the combination of Methamphetamine and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[45]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Methamphetamine caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[46]
Droxidopa	DM5YF4M	Moderate	Additive hypertensive effects by the combination of Methamphetamine and Droxidopa.	Autonomic nervous system disorder [8D87]	[47]
Esketamine	DMVU687	Major	Additive hypertensive effects by the combination of Methamphetamine and Esketamine.	Depression [6A70-6A7Z]	[48]
SODIUM CITRATE	DMHPD2Y	Moderate	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Methamphetamine caused by SODIUM CITRATE mediated altered urine pH.	Discovery agent [N.A.]	[44]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Methamphetamine caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[49]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Methamphetamine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[50]
Sodium acetate anhydrous	DMH21E0	Moderate	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Methamphetamine caused by Sodium acetate anhydrous mediated altered urine pH.	Hypo-osmolality/hyponatraemia [5C72]	[44]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Methamphetamine caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[51]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Methamphetamine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[52]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Methamphetamine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[53]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Methamphetamine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[54]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Methamphetamine caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[55]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Methamphetamine caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[56]
Panobinostat	DM58WKG	Moderate	Decreased metabolism of Methamphetamine caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[57]
Ozanimod	DMT6AM2	Moderate	Increased risk of hyperpyrexia by the combination of Methamphetamine and Ozanimod.	Multiple sclerosis [8A40]	[58]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Methamphetamine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[59]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Methamphetamine caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[60]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Methamphetamine caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[61]
Safinamide	DM0YWJC	Moderate	Decreased metabolism of Methamphetamine caused by Safinamide mediated inhibition of non-CYP450 enzyme.	Parkinsonism [8A00]	[62]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Methamphetamine caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[61]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Aminobenzoate sodium	E00435	517441	Lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Methamphetamine 5 mg tablet	5 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4803).
• [2] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040529.
• [3] Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
• [4] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [5] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [6] BDDCS applied to over 900 drugs
• [7] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [8] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [9] Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend. 2009 Jan 1;99(1-3):231-9.
• [10] Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter. J Med Chem. 2018 Oct 25;61(20):9121-9131.
• [11] Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics. 2001 Aug;11(6):477-87.
• [12] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [13] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [14] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [15] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [16] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [17] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [18] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [19] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [20] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [21] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
• [22] SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72.
• [23] The vesicular monoamine transporter 2: an underexplored pharmacological target. Neurochem Int. 2014 Jul;73:89-97.
• [24] Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91.
• [25] Activation of alpha1-adrenoceptors inhibits growth hormone secretion in humans. Exp Clin Endocrinol Diabetes. 2009 Oct;117(9):460-2.
• [26] Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
• [27] A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
• [28] 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
• [29] An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35.
• [30] A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
• [31] Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673-83.
• [32] Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
• [33] Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
• [34] The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
• [35] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [36] CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
• [37] Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
• [38] Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
• [39] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
• [40] Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
• [41] [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
• [42] Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
• [43] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [44] Anggard E, Jonsson LE, Hogmark AL, Gunne LM "Amphetamine metabolism in amphetamine psychosis." Clin Pharmacol Ther 14 (1973): 870-80. [PMID: 4729903]
• [45] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
• [46] Product Information. Ambien (zolpidem). sanofi-aventis, Bridgewater, NJ.
• [47] Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
• [48] Product Information. Spravato (esketamine). Janssen Pharmaceuticals, Titusville, NJ.
• [49] Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
• [50] Bailey DG, Dresser GK "Natural products and adverse drug interactions." Can Med Assoc J 170 (2004): 1531-2. [PMID: 15136542]
• [51] Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
• [52] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [53] Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
• [54] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [55] Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [56] Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
• [57] Cerner Multum, Inc. "Australian Product Information.".
• [58] Hunter KR, Boakes AJ, Laurence DR, Stern GM "Monoamine oxidase inhibitors and L-dopa." Br Med J 3 (1970): 388. [PMID: 5451592]
• [59] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
• [60] Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [61] Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
• [62] Cusson JR, Goldenberg E, Larochelle P "Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans." J Clin Pharmacol 31 (1991): 462-7. [PMID: 2050833]